477. Antidepressant action of short-acting psychedelics
International Journal of Neuropsychopharmacology September 9, 2026 DOI: 10.1093/ijnp/pyag040.441 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Placebo-controlled Peer reviewed |
|---|---|
| Interventions | 5-MeO-DMT DMT |
| Key findings | Argues that 5-MeO-DMT and DMT show potential for rapid antidepressant effects within 24 hours after brief 15–30 minute interventions, based on early small-scale trials, but emphasizes the need for large, randomized, placebo-controlled trials to confirm replicable and durable efficacy. |
Abstract
Abstract Background Short-acting psychedelics such as 5-MeO-DMT and DMT may induce rapid relief of depressive symptoms after brief but intense psychedelic experiences. Aims & Objectives This presentation examines their clinical pharmacology and therapeutic potential in depression.
Method: Review of clinical data.
Results: Both compounds primarily target serotonergic receptors, notably 5-HT1A and 5-HT2A. Early small-scale trials indicate that short interventions (15–30 minutes) are safe, well tolerated, and can yield significant antidepressant effects within 24 hours. Although long-term data are limited, findings suggest sustained benefits. Discussion & Conclusions Advantages include single-day dosing, reduced reliance on integrative therapy, and straightforward clinical implementation. Key challenges remain, including determining effect duration, maintaining treatment response, optimizing delivery, and clarifying mechanisms of action. Broader acceptance will require large, randomized, placebo-controlled trials demonstrating replicable and durable antidepressant efficacy.